Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …

Background: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5 mg
rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA …

Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

Background: The COMPASS trial (Cardiovascular Outcomes for People using
Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with …

Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

352 Circulation Research February 1, 2019 candidate gene and protein targets for the
development of new drugs. The compendium article by Hegele and Tsimikas10 discusses …

Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …

Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …

Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …

Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …